Ceftobiprole: Can It Treat Staph Bloodstream Infections?

Why does ceftobiprole matter after the pandemic?

The CDC reports that resistant infections beginning in hospitals and associated deaths each increased by at least 15% across seven pathogens between 2019 and 2020. Hospitals faced longer admissions, greater use of invasive devices and disruption to infection prevention. These are historical findings about the pandemic's impact, and they help explain the continuing importance of effective antibacterial treatment. [CDC assessment](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/COVID-19.html).

One treatment advance was the FDA's April 2024 approval of ceftobiprole, marketed as Zevtera, for adults with Staphylococcus aureus bloodstream infections. The indication includes right-sided infective endocarditis, an infection involving the heart's inner lining or valves. Bloodstream infection is a specific, serious illness requiring targeted treatment; the approval does not establish ceftobiprole as a universal solution to antimicrobial resistance. [FDA approval announcement](https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-three-different-uses).

What did the ceftobiprole bloodstream infection trial show?

Published in the New England Journal of Medicine in 2023, ERADICATE randomly assigned 390 adults with complicated staph bloodstream infections to ceftobiprole or daptomycin, with optional aztreonam in the comparator group. Among 387 treated participants with confirmed infection, overall success at day 70 was 69.8% versus 68.7%. Success required survival, improved symptoms, bloodstream clearance, no new infection-related complications and no additional potentially effective antibiotics. These percentages therefore describe a combined outcome, rather than survival alone. [ERADICATE study](https://www.nejm.org/doi/10.1056/NEJMoa2300220).

The study supported noninferiority within a prespecified 15-percentage-point margin; it did not establish superiority. Approximately one-quarter of participants had methicillin-resistant Staphylococcus aureus, or MRSA, limiting firm conclusions about that subgroup alone. The trial was funded by Basilea Pharmaceutica International and the U.S. Department of Health and Human Services. Its findings support an additional treatment option while leaving uncertainty about comparative benefits for particular patients. [Study findings and disclosures](https://www.nejm.org/doi/10.1056/NEJMoa2300220).

How does ceftobiprole work, and what limits its use?

Ceftobiprole is a cephalosporin antibiotic that binds proteins bacteria need to build their cell walls. Its targets include PBP2a, a protein associated with methicillin resistance in staph. Laboratory identification and susceptibility results help clinicians assess whether it is appropriate. The medicine is administered intravenously, and dosing requires adjustment for certain levels of kidney function. [Zevtera prescribing information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2bd685df-7dc6-78a6-e063-6294a90a580b).

Safety considerations include serious allergic reactions, seizures and Clostridioides difficile-associated diarrhea. Reported adverse effects in the bloodstream infection population included nausea, anemia and changes in laboratory measurements. The FDA also highlights increased mortality observed in ventilator-associated bacterial pneumonia, an unapproved use. That warning makes the precise infection being treated particularly important. [FDA safety information](https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-three-different-uses).

The bloodstream trial excluded patients with left-sided endocarditis, prosthetic heart valves and certain other complex conditions. Its results therefore cannot establish equivalent effectiveness in those excluded groups. Clinicians must match the evidence to the patient's diagnosis and circumstances. [Trial eligibility in prescribing information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2bd685df-7dc6-78a6-e063-6294a90a580b).